Cardinal Point Capital Management ULC Has $410,000 Stake in Zoetis Inc. $ZTS

Cardinal Point Capital Management ULC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 74.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,800 shares of the company’s stock after selling 8,256 shares during the period. Cardinal Point Capital Management ULC’s holdings in Zoetis were worth $410,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the last quarter. NewSquare Capital LLC lifted its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Financial Consulate Inc. bought a new position in shares of Zoetis in the 3rd quarter valued at about $39,000. SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth about $42,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of Zoetis stock opened at $127.28 on Tuesday. The company has a 50-day simple moving average of $123.96 and a two-hundred day simple moving average of $136.01. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00. The stock has a market capitalization of $56.09 billion, a price-to-earnings ratio of 21.43, a price-to-earnings-growth ratio of 2.20 and a beta of 0.96. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.69%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a research note on Monday, December 15th. HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. UBS Group set a $136.00 price objective on shares of Zoetis in a research report on Thursday, January 29th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.